CINECA IRIS Institutional Research Information System

DRANDI, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.078
EU - Europa 3.363
AS - Asia 1.609
AF - Africa 80
OC - Oceania 15
SA - Sud America 14
Continente sconosciuto - Info sul continente non disponibili 13
Totale 10.172
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.007
CN - Cina 780
IT - Italia 661
DE - Germania 544
SG - Singapore 478
SE - Svezia 463
IE - Irlanda 366
AT - Austria 310
UA - Ucraina 243
FR - Francia 235
FI - Finlandia 199
KR - Corea 144
PL - Polonia 88
GB - Regno Unito 80
SN - Senegal 72
CA - Canada 59
VN - Vietnam 44
BE - Belgio 33
IN - India 33
ES - Italia 29
GR - Grecia 27
ID - Indonesia 26
NL - Olanda 24
SA - Arabia Saudita 23
RU - Federazione Russa 21
HK - Hong Kong 19
JP - Giappone 19
AU - Australia 14
EU - Europa 13
IR - Iran 12
UZ - Uzbekistan 12
BR - Brasile 9
BY - Bielorussia 9
MX - Messico 9
CH - Svizzera 6
TR - Turchia 5
CZ - Repubblica Ceca 4
AR - Argentina 3
NO - Norvegia 3
PK - Pakistan 3
PT - Portogallo 3
RO - Romania 3
TW - Taiwan 3
ZA - Sudafrica 3
BG - Bulgaria 2
HU - Ungheria 2
LT - Lituania 2
LU - Lussemburgo 2
PR - Porto Rico 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
CO - Colombia 1
CU - Cuba 1
DK - Danimarca 1
DZ - Algeria 1
EG - Egitto 1
GH - Ghana 1
IL - Israele 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MD - Moldavia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
RS - Serbia 1
SC - Seychelles 1
TG - Togo 1
UY - Uruguay 1
Totale 10.172
Salva come PNG Salva come JPEG
Città #
Chandler 709
Beijing 531
Santa Clara 419
Singapore 377
Dublin 365
Vienna 307
Ashburn 262
Jacksonville 207
Ann Arbor 203
Fairfield 197
Nyköping 178
Dearborn 163
Houston 162
Torino 158
Villeurbanne 125
Medford 124
Woodbridge 123
Wilmington 121
San Mateo 107
Princeton 106
Columbus 96
Seattle 84
Florence 79
Warsaw 79
Cambridge 64
Fremont 63
Turin 61
Munich 45
Redwood City 45
Pisa 44
Toronto 42
Washington 39
Brussels 31
Boardman 30
Milan 28
Boston 27
Norwalk 27
Guangzhou 26
Helsinki 26
Jakarta 25
Dong Ket 24
Nürnberg 21
Düsseldorf 19
Nanjing 19
New York 16
Philadelphia 15
Seongnam 15
Bologna 14
Hefei 14
Shanghai 14
Los Angeles 13
Mountain View 12
Rome 12
Chennai 11
Hong Kong 11
Ottawa 11
Redmond 10
Zhengzhou 10
Rotterdam 9
San Diego 9
Tokyo 9
Hangzhou 8
Hebei 8
Kunming 8
Naples 8
Paris 8
San Mauro Torinese 8
Chengdu 7
Jinan 7
Saint Petersburg 7
Des Moines 6
Falls Church 6
Phoenix 6
San Francesco 6
San Jose 6
Nuremberg 5
Perth 5
Pune 5
Tianjin 5
Volpago Del Montello 5
Dallas 4
Falkenstein 4
Linden 4
Liverpool 4
London 4
Margherita Di Savoia 4
Mcallen 4
Provo 4
Seoul 4
Xian 4
Auburn Hills 3
Barcelona 3
Bari 3
Brescia 3
Bucharest 3
Changchun 3
Changsha 3
Costa Mesa 3
Duncan 3
Elâzığ 3
Totale 6.387
Salva come PNG Salva come JPEG
Nome #
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 286
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 267
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients 223
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 207
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 205
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 202
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 199
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 195
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis 175
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 163
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 145
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 140
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 134
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 134
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 133
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 132
New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies 132
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS 127
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 123
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations 119
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 118
Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients 116
Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome 116
Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL) 115
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 115
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 114
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 114
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 113
Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases 112
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 111
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 111
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents 109
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 109
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 107
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone 105
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 105
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 105
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 105
Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2 104
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 104
MYD88L265P MUTATION DETECTION IN WALDENSTRÖM MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING FREE DNA 103
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 103
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 102
Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines 101
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 100
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: Diagnostic challenges and therapeutic options: Two case reports 99
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 98
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 98
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 98
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 97
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 96
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival 96
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease 96
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 95
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 94
Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. 93
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. 91
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 91
Droplet Digital PCR Assay for MYD88L265P 91
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 89
p29ING4 Regulates the Production of Pro-Angiogenic Molecules by Human Myeloma Cells in Normoxic and Hypoxic Conditions Being Involved in Myeloma-Induced Angiogenesis 89
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 87
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 86
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients 86
PHENOTYPIC AND FUNCTIONAL FEATURES OF VGAMMA9/VDELTA2 T CELLS CORRELATE WITH THE MUTATIONAL STATUS OF THE TUMOR IMMUNOGLOBULINE AND WITH DISEASE AGGRESSIVENESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 86
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL 84
THE SURVIVAL OF TUMOR CELLS IN IGVH UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA IS HIGHLY DEPENDENT ON EXOGENOUS SIGNALS DELIVERED BY THE TUMOR MICROENVIRONMENT 83
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 83
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 82
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome 81
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 81
null 80
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders 80
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study 77
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THEIDENTIFICATION OF NOVEL TUMOR-ASSOCIATED ANTIGENS INCHRONIC LYMPHOCYTIC LEUKEMIA 74
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR 73
IGHV UNMUTATED CLL B CELLS ARE MORE PRONE TO SPONTANEOUS APOPTOSIS AND DEPEND FROM THE ANTI-APOPTOTIC EFFECT OF ENVIRONMENTAL SIGNALS 73
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy. 73
Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells 67
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma 67
Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients 66
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma 66
Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms 65
null 64
Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network 62
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma 62
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 57
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC LYMPHOCYTIC LEUKEMIA 55
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). 50
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 49
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma 48
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 48
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 47
Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights 47
The mevalonate pathway as a metabolic target to circumvent multidrug-resistance in chronic lymphocytic leukemia cells (CLL) 45
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders 44
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. 42
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 41
High-Risk Fludarabine-Pretreated B-Cell Chronic Lymphocytic Leukemia's High Response Rate Following Sequential DHAP and Alemtuzumab Administration Though in Absence of Molecular Remission 41
Totale 10.267
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.131
article - articoli 0
book - libri 0
conference - conferenze 15.605
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.736
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020635 0 0 0 0 0 0 164 83 78 104 108 98
2020/20211.113 147 68 64 46 131 43 73 59 120 89 156 117
2021/20221.428 41 26 32 117 59 38 249 91 32 149 342 252
2022/20232.011 184 211 48 212 178 486 127 134 208 86 78 59
2023/2024794 106 176 71 40 42 140 10 53 3 25 33 95
2024/20251.325 13 118 113 235 676 153 17 0 0 0 0 0
Totale 10.499